Cell, gene and tissue therapies ( “ATMPs” – Advanced Therapy Medicinal Products) are booming in Europe, Asia and the United States. In recent years, Belgium has developed a unique expertise in this field, throughout the entire development process: from R&D and clinical trials to biomanufacturing and logistics.
What are the main regulatory challenges and opportunities in terms of the industrialisation of ATMPs? What is the importance of digitalisation along the value chain? How can we take advantage of the Belgian expertise in CDMO (Contract Development & Manufacturing Organization)? What needs to be done to strengthen regional training centres, with a particular focus on ATMP? And how can Belgium continue to develop its leadership in these advanced technologies and innovative therapies?
Find out at the annual event of bio.be/essenscia on 26 September 2022 at Bluepoint in Brussels! Anne Kantardjieff, Vice President Manufacturing at bluebird bio (USA), Hugues Malonne, Director General, DG ” Pre-authorization ” at the Federal Agency for Medicines and Health Products (FAMHP) and a panel with representatives from Catalent Pharma Solutions, Legend Biotech, N-side, pharma.be and Science Park Antwerp University will shed their light on the subject. Geoffrey Pot, chairman of bio.be/essenscia, will draw the final conclusions.
